They have already taken the weight-loss sector by storm - now the blockbuster drugs Ozempic and Mounjaro could do the same ...

Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...

In a first round human trial slimmers in Sweden taking the new drug-currently known as ATR-258-found they burnt fat yet preserved muscle mass.

Hims & Hers stock plummeted around 30% in early trading Monday after Novo Nordisk announced it was ending a collaboration to ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

Wegovy manufacturer ends deal with Hims & Hers to distribute weight loss drug - Hims & Hers had partnered with the Danish ...

The increasing demand for weight-loss jabs such as Mounjaro and Wegovy has helped sales at the firm behind Chemist4U almost ...

Novo Nordisk's U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Hims & Hers stock has fallen nearly 30% on Monday after Novo Nordisk announced it is ending its collaboration with the telehealth company, saying they sell knock-off ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo Nordisk, the maker ...

A new weight loss pill currently undergoing clinical trials could help burn fat and lower blood sugar levels like Ozempic and ...